Vanda Pharmaceuticals Inc.
$322.90M- Market cap
- $329.52M
- Debt
- +$78.23M
- Cash
- −$84.85M
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 ·
Decision snapshot: VNDA stock price vs INFN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INFN's multiple
Needs INFN P/S.
Implied fair value · at VNDA's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VNDA FY 2025 (ended Dec 31, 2025) · INFN FY 2024 (ended Dec 28, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Infinera Corp · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
5.74x
Net debt / EBITDA
Leverage against operating earnings
0.05x
-11.94x
Cash and equivalents
Liquid reserves on the balance sheet
$84.85M
$145.81M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
VNDA vs SUPN
CATALYST PHARMACEUTICALS, INC.
VNDA vs CPRX
Harmony Biosciences Holdings, Inc.
VNDA vs HRMY
ELI LILLY & Co
VNDA vs LLY
INCYTE CORP
VNDA vs INCY
Sarepta Therapeutics, Inc.
VNDA vs SRPT
CIENA CORP
VNDA vs CIEN
VIAVI SOLUTIONS INC.
VNDA vs VIAV
JUNIPER NETWORKS INC
VNDA vs JNPR
CISCO SYSTEMS, INC.
VNDA vs CSCO
Arista Networks, Inc.
VNDA vs ANET
Motorola Solutions, Inc.
VNDA vs MSI
$78.23M
$668.41M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.